Statistics about Health, Pharma & Medtech in United States
Statistics
- Global Wholehealth Partners Corp operating profit 2019-2022
- Global Wholehealth Partners Corp liabilities 2014-2022
- Immunogen, Inc. total equity 2018-2022
- Immunovant, Inc. total equity 2019-2023
- Global Wholehealth Partners Corp net cash 2019-2022
- Indaptus Therapeutics, Inc. total equity 2019-2023
- Inhibikase Therapeutics total equity 2019-2023
- Savara revenue 2015-2020
- Immunome total equity 2019-2023
- Shattuck Labs operating profit 2019-2023
- Intra-Cellular Therapies net income 2019-2023
- Satsuma Pharmaceuticals, Inc. total assets 2018-2022
- Shattuck Labs total assets 2019-2023
- Glycomimetics net income 2019-2023
- Galecto net income 2019-2023
- Galecto operating profit 2019-2023
- Savara net cash 2019-2023
- Shattuck Labs net cash 2019-2023
- Galecto liabilities 2019-2023
- Innovation1 Biotech gross profit 2019-2023
- Satsuma Pharmaceuticals, Inc. net cash 2018-2022
- Savara liabilities 2019-2023
- Jaguar Health net income 2019-2023
- Shattuck Labs liabilities 2019-2023
- Jaguar Health revenue 2018-2022
- Satsuma Pharmaceuticals, Inc. liabilities 2018-2022
- Intra-Cellular Therapies revenue 2019-2023
- International Stem Cell revenue 2019-2023
- Innovation1 Biotech revenue 2019-2023
- Johnson & Johnson net income 2010-2014
- Innovation1 Biotech net income 2018-2022
- Savara operating profit 2019-2023
- Immunitybio liabilities 2019-2023
- Sensei Biotherapeutics total equity 2019-2023
- Q Biomed gross profit 2020-2022
- Infinity Pharmaceuticals total assets 2018-2022
- Skye Bioscience liabilities 2019-2023
- G1 Therapeutic revenue 2020-2023
- G1 Therapeutic net income 2019-2023
- Ideaya Biosciences total equity 2019-2023
- Senti Biosciences operating profit 2021-2023
- Intensity Therapeutics total assets 2022-2023
- Sensei Biotherapeutics operating profit 2020-2023
- Integrated Biopharma Inc total assets 2020-2024
- Impel Pharmaceuticals total assets 2020-2022
- Igm Biosciences total equity 2019-2023
- Genelux total assets 2022-2023
- Genelux total equity 2021-2023
- Immix Biopharma total assets 2020-2023
- Immunic total assets 2019-2023
- Immuneering total assets 2020-2023
- In8Bio total assets 2020-2023
- Genelux liabilities 2022-2023
- Genelux net cash 2022-2023
- Gelesis Holdings net cash 2020-2022
- G1 Therapeutic operating profit 2019-2023
- Igc Pharma, Inc. total equity 2019-2023
- Ikena Oncology total assets 2020-2023
- Immuneering total equity 2019-2023
- Ironwood Pharmaceuticals net income 2019-2023
- Gossamer Bio net income 2019-2023
- Gossamer Bio liabilities 2019-2023
- Iovance Biotherapeutics, Inc. net income 2013-2014
- Ionis Pharmaceuticals net income 2018-2022
- Insmed total equity 2019-2023
- Intensity Therapeutics total equity 2021-2023
- Infinity Pharmaceuticals total equity 2018-2022
- Immunic total equity 2019-2023
- G1 Therapeutic total assets 2019-2023
- Impel Pharmaceuticals total equity 2019-2022
- In8Bio total equity 2019-2023
- Integrated Biopharma Inc total equity 2020-2024
- G1 Therapeutic total equity 2019-2023
- G1 Therapeutic liabilities 2019-2023
- Immix Biopharma total equity 2019-2023
- G1 Therapeutic net cash 2019-2023
- Ikena Oncology total equity 2019-2023
- Imago Biosciences, Inc. total equity 2019-2021
- Imago Biosciences, Inc. total assets 2020-2021
- Igc Pharma, Inc. total assets 2019-2023
- Gossamer Bio total assets 2019-2023
- Prophase Labs operating profit 2019-2023
- Glucose Health net income 2012-2013
- Immuneering net cash 2020-2023
- Glucose Health gross profit 2010-2016
- Impel Pharmaceuticals net cash 2020-2022
- Igm Biosciences net cash 2019-2023
- Immix Biopharma net cash 2020-2023
- Ikena Oncology net cash 2020-2023
- Provention Bio, Inc. operating profit 2018-2022
- Glucose Health operating profit 2012-2016
- Insmed total assets 2019-2023
- Imago Biosciences, Inc. net cash 2020-2021
- Igc Pharma, Inc. net cash 2019-2023
- Ideaya Biosciences net cash 2019-2023
- Prelude Therapeutics operating profit 2019-2023
- Intensity Therapeutics liabilities 2022-2023
- Insmed liabilities 2019-2023
- Skye Bioscience operating profit 2019-2023
- Immunic liabilities 2019-2023